Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis;Valor predictivo de la lipoproteína (a) y la apolipoproteína A1 en pacientes con obstrucción coronaria valorada angiográ ficamente

Medicina Clinica

Volumn 128, Issue 16, 2007, Pages 601-604

  Sagastagoitia, José Domingo ^a,b   Vacas, Marta ^b   Sáez, Yolanda ^b   Narváez, Idoia ^b   De Lafuente, Jesús Pablo Sáez ^c   Molinero, Enrique ^a   Lafita, Manuel ^b   Magro, Ana ^b   Escobar, Antonio ^a   Martínez, Begoña ^b   Santos, Mónica ^b   Caso, Rosario ^b   Iriarte, José Antonio ^b  

^a HOSPITAL DE BASURTO   (Spain)

^b Fundacion para la Investigacion Y Docencia de Las Enfermedades Cardiovasculares (FIDEC)   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Coronary obstruction; Hemostatic markers; Inflammation; Lipids

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; FEMALE; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE;

EID: 34249943991     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13101742     Document Type: Article

References (23)

1. Oporil S, Oberman A. Non traditional cardiovascular risk factors. Am J Med Sci. 1999;317:193-207.
2. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al, for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary event rates across the WHO MONICA Project populations. Lancet. 2000;355:675-87.
3. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara MY, Ordovas JM, Davis CE. Lipoprotein (a) levels and risk of coronary heart disease in men. JAMA. 1994;271:999-1003.
4. Batalla Celorio A, Rodríguez Reguero JJ, Iglesias Cubero G, Hevia Nava S, Braga Fernández S, Fernández Bustillo E, et al. La lipoproteína (a) es predictora de severidad angiográfica en varones menores de 50 años con inicio clínico de enfermedad coronaria. Rev Esp Cardiol. 2000;53:1047-51.
5. Folsom AR. Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinolysis. 1999;10 Suppl 1:13-6.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appelby P, et al. Fibrin D-dimer and coronary heart disease: prospective study and metaanalysis. Circulation. 2001;103:2323-7.
7. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-age men and women. The Scottish Health Study. Eur Heart J. 1998;19:55-62.
8. Cushman M, Lemaitre RN, Kuller LH, Psaty RM, Macy EM, Sharret AR, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999;19:493-8.
9. Ross R. The pathogenesis of atherosclerosis: a perspective from the 1990s. Nature. 1993;362: 801-9.
10. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
11. Iyigun I, Bakirei Y. Plasma concentrations of C-reactive protein and fibrinogen in ischaemic stroke. J Int Med Res. 2002;30:591-6.
12. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169: 203-14.
13. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease; prospective study and updated meta-analyses. BMJ. 2000; 321:199-204.
14. a ed. Barcelona: SignoSA; 1998.
15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352:1685-95.
16. Madjid M, Awan I, Willerson JT, Casscells W. Leukocyte count and coronary heart disease. J Am Coll Cardiol. 2004;44:1945-56.
17. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women. The Cardiovascular Health Study. Circulation. 2005;112:25-31.
18. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 1989;339: 301-3.
19. Viles-González JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol. 2003; 18:286-94.
20. Kunihisa M, Keiko N. Risk factors that discriminate «high- risk» from «low-risk» Japanese patients with coronary artery disease. Jpn Circ J. 2000;64:825-30.
21. Dahlen GH, Weinehall L, Stenlund H, Jansson JH, Hallmans G, Huhtasaari F. Lipoprotein (a) and cholesterol levels act synergistically and apolipoprotein A-1 is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control from Sweden. J Intern Med. 1998;244:425-30.
22. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effects of recombinant Apo A1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomised controlled trial. JAMA. 2003;290: 2292-300.
23. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezun A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study. Lancet. 2004;364:937-52.